Zacks Research Analysts Cut Earnings Estimates for Neogen

Neogen Co. (NASDAQ:NEOG) – Zacks Research decreased their Q2 2025 earnings per share estimates for Neogen in a report released on Thursday, January 2nd. Zacks Research analyst R. Department now expects that the company will post earnings of $0.11 per share for the quarter, down from their prior estimate of $0.12. The consensus estimate for Neogen’s current full-year earnings is $0.50 per share. Zacks Research also issued estimates for Neogen’s FY2027 earnings at $0.72 EPS.

Neogen (NASDAQ:NEOG) last announced its quarterly earnings data on Thursday, October 10th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The company had revenue of $217.00 million for the quarter, compared to analysts’ expectations of $215.05 million. Neogen had a negative net margin of 2.58% and a positive return on equity of 2.80%. The firm’s quarterly revenue was down 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.11 EPS.

NEOG has been the subject of several other research reports. Guggenheim assumed coverage on Neogen in a research note on Thursday, December 19th. They issued a “buy” rating and a $15.00 price target for the company. StockNews.com upgraded Neogen to a “sell” rating in a research note on Monday, September 30th.

Neogen Stock Up 2.6 %

Shares of NASDAQ:NEOG opened at $12.25 on Monday. The stock has a fifty day simple moving average of $13.65 and a two-hundred day simple moving average of $15.19. The stock has a market capitalization of $2.65 billion, a price-to-earnings ratio of -111.36 and a beta of 1.21. Neogen has a 12-month low of $11.46 and a 12-month high of $19.88. The company has a current ratio of 4.41, a quick ratio of 2.79 and a debt-to-equity ratio of 0.28.

Insider Transactions at Neogen

In other news, CEO John Edward Adent acquired 14,500 shares of Neogen stock in a transaction that occurred on Friday, October 11th. The stock was bought at an average price of $13.80 per share, for a total transaction of $200,100.00. Following the completion of the transaction, the chief executive officer now owns 216,477 shares in the company, valued at $2,987,382.60. The trade was a 7.18 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.13% of the company’s stock.

Institutional Trading of Neogen

Hedge funds have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC increased its position in Neogen by 142.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,982 shares of the company’s stock valued at $33,000 after acquiring an additional 1,165 shares during the last quarter. Headlands Technologies LLC increased its position in Neogen by 264.1% during the second quarter. Headlands Technologies LLC now owns 3,397 shares of the company’s stock valued at $53,000 after acquiring an additional 2,464 shares during the last quarter. Neo Ivy Capital Management purchased a new stake in Neogen during the third quarter valued at $66,000. Marco Investment Management LLC purchased a new stake in Neogen during the third quarter valued at $169,000. Finally, Raymond James Trust N.A. bought a new stake in Neogen during the third quarter valued at about $182,000. Hedge funds and other institutional investors own 96.73% of the company’s stock.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.